Agreements reached under this partnership
Business alliance- 1
Development and marketing in Japan of Qilu’s follitropin alfa (genetically engineered) biosimilar
- 2
Mochida Pharmaceutical will develop the product with the aim of obtaining marketing approval in Japan
- 3
Mochida Pharmaceutical will work with Qilu and seek an early launch
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
| Item | Details |
|---|---|
| Name of alliance partner | Qilu Pharmaceutical Co., Ltd. |
| Alliance partner's business activities | One of China’s leading pharmaceutical companies, engaged in research and development, manufacturing, and sales on an integrated basis |
| Alliance partner's location | Jinan, Shandong Province, China |
| Alliance partner's net sales | Approximately USD 6 billion (2024) |
| Type of alliance | Business alliance |
| Details of the alliance | Development and marketing in Japan of Qilu’s follitropin alfa (genetically engineered) biosimilar, Mochida Pharmaceutical will develop the product with the aim of obtaining marketing approval in Japan, Mochida Pharmaceutical will work with Qilu and seek an early launch |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The partnership is intended to strengthen Mochida Pharmaceutical’s efforts in obstetrics and gynecology, a priority area for the company, and further expand its biosimilar business. The company also aims to offer this product in the Japanese market as a new infertility treatment option and contribute to improving patients’ quality of life.